



Pharmacovigilance Challenges of COVID-19 Vaccine

Guest Editor:

Prof. Ugo Moretti

Section of Pharmacology,
Department of Diagnostics and
Public Health, University of
Verona, Verona, Italy

Deadline for manuscript
submissions:

closed (30 November 2024)

Message from the Guest Editor

The COVID-19 pandemic challenged all healthcare systems, which had to find ways to treat the disease and prevent its spread. Pharmaceutical companies faced the challenge of developing new vaccines, and health authorities had to evaluate them and authorize their release to the market. Once the vaccines were distributed, each country had to decide how to distribute them, educate healthcare professionals on their administration, and establish a proactive surveillance system to detect any potential safety issues.

The success of the vaccination campaign depended on the collaboration of the whole of society. This Special Issue aims to provide an overview of all aspects of the pharmacovigilance system that was put in place and is still in action, as well as future perspectives.

We welcome original papers, reviews, and studies that deal with the pharmacovigilance system, safety signals, immunology mechanisms, medication errors, and the past and future challenges related to COVID-19 vaccination.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)